Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biotechnology company built on RNA interference, a technique that switches off the genes behind certain diseases. At about $31 billion, the stock features on our list of 9 New Contenders for the S&P 500 Index. It stands out as a rare large biotech that has turned sustainably profitable under standard […]